Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Host immunity recognizes and eliminates most early tumor cells, yet immunological
checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to …

We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from
bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor …

Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers;
however, durable response is limited to only a subset of patients. Discovery of blood-based …

Abstract Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional
therapies for treatment of advanced or metastatic cancer. However, the factors determining …

Many systems on our planet shift abruptly and irreversibly from the desired state to an
undesired state when forced across a “tipping point”. Some examples are mass extinctions …

Cancer immunotherapy using antibodies that target immune checkpoints has delivered
outstanding results. However, responses only occur in a subset of patients, and it is not fully …

The idea that chemotherapy can be used in combination with immunotherapy may seem
somewhat counterproductive, as it can theoretically eliminate the immune cells needed for …

Inflammation is thought to play an important role in the pathogenesis of vascular diseases.
Lipoprotein‐associated phospholipase A2 (Lp‐PLA2) mediates vascular inflammation …

Developing predictive biomarkers that can detect the tipping point before metastasis of
hepatocellular carcinoma (HCC), is critical to prevent further irreversible deterioration. To …